Repros Therapeutics (RPRX) Reports Q4 Loss of $0.16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results
March 31, 2017 9:15 AM EDTTHE WOODLANDS, Texas, March 31, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the fourth quarter and year ended December 31, 2016.
Financial Results
Net loss for the three month period ended December 31, 2016, was ($4.0) million or ($0.16) per share as compared to a net loss of ($6.3) million or ($0.26) per share for the same period in 2015. The net loss for the year ended December 31, 2016, was ($17.3) million or ($0.70) per share as compared to a net loss of ($29.2) million or ($1.20) per share for 2015. ... More
